1. Introduction {#sec1}
===============

Pancreatic cancer (PC) is one of the most lethal malignant neoplasms in the world \[[@B1]\]. The long-term prognosis of patients with PC is poor, with a median survival of 8.5--11 months for those with metastatic disease even with aggressive treatment \[[@B2], [@B3]\]. To date, surgical excision is the only curative treatment for PC; however, only 10--15% of patients are eligible for this procedure \[[@B4]\]. Chemo/radiotherapy is used to palliate symptoms and improve survival in patients with advanced disease. Therefore, accurate clinical staging and identification of prognostic factors are crucial for estimating prognosis and selecting appropriate treatment modalities.

Although the pathological stage of PC is considered the most significant prognostic factor, it is difficult to obtain tumor tissues for analysis in a significant number of patients. Recently, several studies have demonstrated that the neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) could serve as a simple immune function index and may be of prognostic significance in patients with various solid tumors \[[@B5], [@B6]\]. However, the relationship between NLR/PLR and clinical outcomes in patients with PC remains controversial. As they are derived from routine laboratory tests, NLR and PLR are easy to obtain and may serve an important function in monitoring PC progression as well as in predicting patient survival. Therefore, we performed this study to evaluate the prognostic values of NLR and PLR in patients with PC.

2. Methods {#sec2}
==========

2.1. Published Studies\' Search and Selection Criteria {#sec2.1}
------------------------------------------------------

We followed the methods of Jeong et al. \[[@B7]\]. Relevant articles were obtained by searching the PubMed and MEDLINE databases through December 31, 2017. These databases were searched using the following key words: "pancreatic cancer," "survival," and "neutrophil-to-lymphocyte ratio or platelet-to-lymphocyte ratio." The titles and abstracts of all searched articles were screened. Review articles were also screened to identify additional eligible studies. Articles related to studies of human PC (other than pancreatic neuroendocrine tumors) and those with data pertaining to the correlation between inflammatory markers and survival were included. Articles were excluded if they were case reports or nonoriginal articles, or if not written in English. This protocol was reviewed and approved by the Institutional Review Board of Eulji Hospital (approval number NON2017-002).

2.2. Data Extraction {#sec2.2}
--------------------

Data from all eligible studies were extracted by two independent authors. The following data were extracted from each of the eligible studies \[[@B8]--[@B41]\]: the first author\'s name, year of publication, study location, number of patients analyzed, tumor stage, treatment modality, criteria for each inflammatory marker, rate of patients with high inflammatory marker values, and information on the correlations between inflammatory markers and survival. For quantitative aggregation of survival results, the correlations between inflammatory markers and the overall survival (OS) rates were analyzed according to the reported hazard ratio (HR) using one of three methods. In studies not quoting the HR or its confidence interval (CI), these variables were calculated from the presented data using the HR point estimate, log-rank statistic or its *P* value, and the *O*-*E* statistic (i.e., the difference between the numbers of observed and expected events) or its variance. If these data were unavailable, the HR was estimated using the total number of events, number of patients-at-risk in each group, and the log-rank statistic or its *P* value. Finally, if the only useful data were in the form of graphical representations of survival distributions, survival rates were extracted at specified times to reconstruct the HR estimate and its variance under the assumption that patients were censored at a constant rate during the time intervals \[[@B42]\]. The published survival curves were read independently by two authors to reduce variability. The HRs were then combined into an overall value using Peto\'s method \[[@B43]\].

2.3. Statistical Analyses {#sec2.3}
-------------------------

To perform the meta-analysis, all data were analyzed using the Comprehensive Meta-Analysis software package (Biostat, Englewood, NJ, USA). We investigated high values of inflammatory markers (the NLR and PLR) and their correlations with OS rates in patients with PC. Heterogeneity between the studies was checked by the *Q* and *I*^2^ statistics and expressed as *P* values. Additionally, sensitivity analysis was conducted to assess the heterogeneity of eligible studies and the impact of each study on the combined effect. Because eligible studies were evaluated in various populations with different tumor stages and treatments, a random-effects model was applied as it was more suitable than a fixed-effects model for interpreting the influence of inflammatory markers. Begg\'s funnel plot and Egger\'s test were used to assess publication bias; if significant publication bias was found, fail-safe *N* and trim-fill tests were performed to determine the degree of such bias. The results were considered statistically significant at *P* \< 0.05.

3. Results {#sec3}
==========

3.1. Selection and Characteristics of the Studies {#sec3.1}
-------------------------------------------------

One hundred forty-seven reports were retrieved from the database; 37 articles were excluded as they were duplicates while a further 36 were excluded because of insufficient or no information. Additionally, 40 reports were excluded because they described other diseases (*n* = 29), were published in a language other than English (*n* = 1), or were nonoriginal research articles (*n* = 10). Finally, 34 studies that encompassed 7105 patients with PC were included in this meta-analysis ([Figure 1](#fig1){ref-type="fig"} and [Table 1](#tab1){ref-type="table"}).

3.2. Meta-Analysis {#sec3.2}
------------------

First, the relationships between high NLR and PLR values and PC were investigated. Overall, the rates of high NLR and PLR as determined using the random-effects model were 0.379 (95% CI 0.310--0.454) and 0.490 (95% CI 0.438--0.543), respectively. Additional data, as well as the results of heterogeneity and publication bias analyses, are shown in [Table 2](#tab2){ref-type="table"}. Patients with lower tumor stages (I and II) showed higher NLRs than those with higher tumor stages (III and IV). Additionally, the rate of high NLR was higher in patients who had undergone surgery than in those who received other treatments. There were no differences in the rates of high NLR and PLR between study locations. In comparison between higher and lower criterion subgroups, higher criteria of NLR showed significantly higher rate of high NLR than lower criteria of NLR. However, in PLR, there was no significant difference between higher and lower criteria of PLR.

Next, the correlations between high values of these inflammatory markers and OS rates were investigated. High NLR and PLR values were significantly correlated with poorer OS (HR 1.737, 95% CI 1.502--2.009 and HR 1.143, 95% CI 1.037--1.259, resp.; [Table 3](#tab3){ref-type="table"}). Subgroup analyses based on study location, tumor stage, treatment, and cutoffs were conducted. With respect to NLR, all subgroups except for patients who underwent chemotherapy and/or radiotherapy showed significant correlations between high NLR and a poorer OS; a high NLR had no prognostic role in patients who underwent chemo- or radiotherapy (HR 0.922, 95% CI 0.269--3.162). Patients with high PLR values only showed poorer OS if they were Asian or underwent mixed treatment (i.e., surgery plus chemo/radiotherapy).

4. Discussion {#sec4}
=============

In this meta-analysis of 34 studies comprising 7105 patients with PC, we showed that the NLR and PLR constitute novel prognostic markers for predicting the prognosis of patients with PC. To the best of our knowledge, our meta-analysis is the first to investigate this relationship. The results of our meta-analysis demonstrated that high NLR and PLR values were found to be correlated with poor OS in patients with PC.

Although there was no significant difference in PLR among patients in the present series, a high NLR was frequently found in patients with lower tumor stages (I and II) and in those who had undergone surgery. In view of the relatively high likelihood of poor outcomes in patients with PC regardless of stage, patients with lower-stage tumors that are usually limited to the pancreas are most likely to undergo surgical resection \[[@B44]\]. The prognosis is better in patients with lower tumor stage than in those with higher stage \[[@B45]\]. In other types of cancer, a lower tumor stage was associated with lower NLR levels \[[@B46], [@B47]\]. In our study, the subgroup with low tumor stages (I-II) showed higher rate of high NLR than the subgroup with high tumor stages (III-IV) (0.656 versus 0.373). However, because the subgroup with low tumor stage included only one eligible study, further studies will be needed to obtain the detailed information of PC with low stage. A plausible explanation for our apparently counterintuitive results is that a subset of patients included in the analysis underwent palliative surgery \[[@B9], [@B35]--[@B37]\]. Moreover, the time of obtaining blood samples for measuring neutrophils, lymphocytes, and platelets before treatment might be an important limiting factor. Another possible bias in our data is the presence of biliary sepsis; approximately 56% of PC patients present with obstructive jaundice and are more susceptible to bacterial infection owing to bile duct obstruction \[[@B48], [@B49]\]. Few studies included in our meta-analysis controlled for biliary infection by excluding patients with this septic condition; therefore, such comorbidities may have influenced our findings \[[@B13], [@B26], [@B28]\].

The exact mechanisms between high NLR/PLR values and poor outcomes in patients with PC are unclear. Systemic inflammation plays decisive roles at different stages of tumor development, including initiation, promotion, malignant conversion, invasion, and metastasis. Inflammation may enhance tumor initiation through genetic mutations, genomic instability, and epigenetic modifications and can activate tissue repair responses that induce proliferation of premalignant cells and prolong their survival. Inflammation also stimulates angiogenesis, causes immunosuppression, and promotes the formation of tumor-supporting microenvironments that ultimately promote metastasis \[[@B50]\]. The close association between increased systemic inflammatory responses (as assessed by NLR and PLR) and poor prognosis may also be related to cancer cell activation of inflammatory processes. Cancer-related inflammation suppresses antitumor immunity by recruiting regulatory T cells and activating chemokines, resulting in tumor progression. Tumors also secrete vascular endothelial growth factor (VEGF), a vascular permeability factor that induces persistent extravasation of fibrin and fibronectin and continuous generation of the extracellular matrix \[[@B51]\]. Platelets are a critical source of cytokines, especially transforming growth factor-beta as well as VEGF, which can promote cancer progression by enhancing angiogenesis \[[@B50]--[@B52]\]. Proinflammatory cytokines such as interleukins 1 and 6 can promote megakaryocyte proliferation; this results in thrombocytosis, which is a negative prognostic marker in several cancers \[[@B53]--[@B55]\]. Therefore, inflammatory markers might be an indicator of prognosis. Recently, NLR and PLR have now been investigated as prognostic factors. The measurement of the NLR and PLR is straightforward and convenient and is potentially useful in daily oncologic practice.

Our study found that patients with PC who have high NLR values exhibit poor OS which was consistent with the results in other types of malignancies \[[@B46], [@B47], [@B56]\]. Subgroup analysis of NLR stratified by study location, tumor stage, treatment, and threshold criteria also demonstrated that a high NLR had a negative effect on OS except in patients who underwent chemotherapy and/or radiotherapy. The NLR after chemo- and radiotherapy did not correlate with OS. NLR is a relative value that fluctuates depending on neutrophil or lymphocyte changes and may therefore be affected by chemotherapy, radiotherapy, or granulocyte colony-stimulating factor administration \[[@B29]\]. These factors might induce changes in the number of neutrophils or lymphocytes; clinicians should consider these conditions in clinical practice. Several studies demonstrated that postchemotherapy NLR change was an independent prognostic marker \[[@B8], [@B29], [@B32]\]. Given potential chemotherapy- or radiotherapy-related toxicities, increased NLR values after treatment may help physicians decide to transfer affected patients to early palliative care, whereas a decrease in the NLR after chemo- or radiotherapy can be considered an early predictor of response to treatment.

High PLR could also predict OS of patients with PC in accordance with other malignancies \[[@B46], [@B47], [@B56]\]. However, in subgroup analyses, a high PLR was associated with worse OS only in Asian patients and in those who underwent mixed treatment (surgery plus chemo/radiotherapy). Our meta-analysis demonstrated that NLR is a better predictor of prognosis of patients with PC than PLR, which is also consistent with the results of previous studies \[[@B35], [@B57]\]. Our analysis may provide important information to support treatment decision-making, including pursuing more aggressive treatments.

There were several limitations in this meta-analysis. First, all of the included studies were retrospective and were thereby more prone to some biases. Second, information about PLR in patients who underwent surgical treatment could not be obtained from the eligible studies. Third, a comparison between pre- and posttreatment inflammatory marker values could not be performed owing to insufficient information.

In conclusion, high NLR and PLR values are useful predictors of worse survival in patients with PC. These parameters can therefore be useful for identifying high-risk patients with PC and for determining individual treatment plans.
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###### 

Main characteristics of the studies included in this meta-analysis.

  Author, year                        Location    Tumor type   Tumor stage   Tx option   Parameter   Criteria   Criterion subgroup   Number of patients         
  ----------------------------------- ----------- ------------ ------------- ----------- ----------- ---------- -------------------- -------------------- ----- -----
  Alagappan et al., 2016 \[[@B24]\]   USA         PDAC         ND            Mixed       NLR         5          High                 208                  ND    ND
                                                                             PLR         200         High       208                  ND                   ND    
  An et al., 2010 \[[@B36]\]          China       PC           III-IV        CTx         NLR         5          High                 95                   ND    ND
  Asaoka et al., 2016 \[[@B21]\]      Japan       PC           I-III         Mixed       NLR         2.7        Low                  46                   20    26
  Asari et al., 2016 \[[@B22]\]       Japan       PDAC         I-IV          Mixed       NLR         3          Low                  184                  62    122
  Ben et al., 2015 \[[@B28]\]         China       PDAC         I-III         Surgery     NLR         2          Low                  381                  267   114
  Chawla et al., 2017 \[[@B37]\]      USA         PDAC         I-IV          Mixed       NLR         3.3        Low                  217                  107   110
                                                                             PLR         175         High       217                  107                  110   
  Chen et al., 2017 \[[@B10]\]        China       PDAC         III-IV        CTx         NLR         2.78       Low                  132                  78    54
  Cheng et al., 2016 \[[@B25]\]       China       PC           I-II          Mixed       NLR         2          Low                  195                  128   67
  Inoue et al., 2015 \[[@B30]\]       Japan       PDAC         I-IV          Mixed       NLR         2          Low                  440                  300   140
                                                                                         PLR         150        Low                  440                  201   239
  Kishi et al., 2015 \[[@B27]\]       Japan       PC           III/IV        CTx/RTx     NLR         5          High                 65                   7     58
                                                                                         PLR         150        Low                  65                   30    35
  Kou et al., 2016 \[[@B23]\]         Japan       PC           III-IV        CTx         NLR         5          High                 306                  49    257
                                                                             PLR         150         Low        306                  180                  126   
  Lee et al., 2016 \[[@B19]\]         Korea       PDAC         III-IV        CTx         NLR         5          High                 82                   20    62
                                                                             PLR         150         Low        82                   36                   46    
  Liu et al., 2017 \[[@B14]\]         China       PDAC         I-IV          Mixed       NLR         4.5        High                 386                  63    323
  Luo et al., 2015 \[[@B29]\]         China       PDAC         III-IV        CTx         NLR         3.1        Low                  403                  194   209
  Martin et al., 2014 \[[@B31]\]      Australia   PC           III-IV        CTx/RTx     NLR         5          High                 124                  60    64
                                                                             PLR         200         Low        124                  75                   49    
  Mitsunaga et al., 2016 \[[@B41]\]   Japan       PC           III-IV        CTx         NLR         5          High                 195                  ND    ND
  Montes et al., 2017 \[[@B11]\]      Spain       PC           III-IV        CTx         NLR         2.455      Low                  39                   ND    ND
  Piciucchi et al., 2017 \[[@B12]\]   Italy       PDAC         ND            Mixed       NLR         5          High                 206                  60    144
  Shirai et al., 2015 \[[@B15]\]      Japan       PDAC         ND            ND          NLR         5          High                 131                  15    116
                                                                             PLR         150         Low        131                  73                   58    
  Sierzega et al., 2017 \[[@B13]\]    Poland      PDAC         I-III         Mixed       NLR         5          High                 442                  119   323
  Sugiura et al., 2013 \[[@B34]\]     Japan       PDAC         III-IV        Mixed       NLR         4          Low                  83                   36    47
  Sugiura et al., 2017 \[[@B9]\]      Japan       PDAC         III-IV        CTx         NLR         4          Low                  129                  62    67
  Szkandera et al., 2014 \[[@B33]\]   Austria     PDAC         I-IV          Mixed       NLR         3.25       Low                  474                  247   227
  Tao et al., 2016 \[[@B16]\]         China       PDAC         I-IV          Mixed       NLR         2.5        Low                  154                  84    70
                                                                             PLR         150         Low        154                  81                   73    
  Takakura et al., 2016 \[[@B26]\]    Japan       PC           I-III         Mixed       NLR         4.3        High                 28                   ND    ND
  Teo et al., 2013 \[[@B40]\]         Ireland     PDAC         III-IV        CTx         NLR         3          Low                  85                   58    27
  Tsujita et al., 2017 \[[@B8]\]      Japan       PC           II-IV         Mixed       NLR         3          Low                  86                   ND    ND
  Vivaldi et al., 2016 \[[@B18]\]     Italy       PC           III-IV        CTx         NLR         4          Low                  119                  21    98
  Wang et al., 2012 \[[@B35]\]        China       PDAC         I-IV          Mixed       NLR         5          High                 177                  32    145
  Wu et al., 2016 \[[@B17]\]          China       PDAC         III-IV        Mixed       NLR         5          High                 233                  57    176
  Xu et al., 2017 \[[@B38]\]          China       PDAC         I-IV          Mixed       NLR         3.8        Low                  265                  71    194
                                                                                         PLR         182.1      High                 265                  87    178
  Xue et al., 2014 \[[@B32]\]         Japan       PDAC         III-IV        CTx         NLR         5          High                 252                  40    212
                                                                             PLR         150         Low        252                  148                  104   
  Yamada et al., 2016 \[[@B20]\]      Japan       PC           I-IV          Mixed       NLR         3          Low                  379                  130   249
                                                                             PLR         150         Low        379                  192                  187   
  Yu et al., 2017 \[[@B39]\]          China                                                                                                                     
  Training set                                    PC           III-IV        CTx         NLR         3.42       Low                  139                  93    46
  Validation set                                  PC           III-IV        CTx         NLR         3.42       Low                  225                  131   94

Tx: Treatment; PDAC: pancreatic ductal adenocarcinoma; PC: pancreatic cancer; CTx: chemotherapy; RTx: radiation therapy; NLR: neutrophil-to-lymphocyte ratio; PLR: platelet-to-lymphocyte ratio; ND: no description. "Mixed" treatment indicates surgery plus chemotherapy/radiotherapy.

###### 

Estimated rates of high neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios.

                             Number of subset   Fixed effect (95% CI)   Heterogeneity test (*P* value)   Random effect (95% CI)   Egger\'s test (*P* value)
  -------------------------- ------------------ ----------------------- -------------------------------- ------------------------ ---------------------------
  *NLR*                                                                                                                           
  Overall                    29                 0.422 (0.409, 0.436)    \<0.001                          0.379 (0.310, 0.454)     0.086
  Location                                                                                                                        
   Asia                      22                 0.426 (0.411, 0.442)    \<0.001                          0.370 (0.285, 0.464)     0.067
   Non-Asia                  7                  0.413 (0.388, 0.438)    \<0.001                          0.406 (0.295, 0.528)     0.855
  Tumor stage                                                                                                                     
   I and II                  1                  0.656 (0.587, 0.720)    1.000                            0.656 (0.587, 0.720)     ---
   III and IV                14                 0.406 (0.384, 0.428)    \<0.001                          0.373 (0.273, 0.484)     0.375
  Treatment                                                                                                                       
   Surgery                   1                  0.701 (0.653, 0.745)    1.000                            0.701 (0.653, 0.745)     ---
   Chemotherapy              10                 0.426 (0.401, 0.451)    \<0.001                          0.403 (0.276, 0.544)     0.571
   Chemo- and radiotherapy   2                  0.399 (0.325, 0.478)    \<0.001                          0.258 (0.045, 0.721)     ---
   Mixed                     15                 0.401 (0.385, 0.418)    \<0.001                          0.380 (0.294, 0.474)     0.359
  NLR criteria                                                                                                                    
   High (\>4)                14                 0.246 (0.230, 0.263)    \<0.001                          0.237 (0.184, 0.299)     0.650
   Low (≤4)                  15                 0.530 (0.514, 0.547)    \<0.001                          0.533 (0.459, 0.606)     0.932
  *PLR*                                                                                                                           
  Overall                    13                 0.482 (0.464, 0.500)    \<0.001                          0.490 (0.438, 0.543)     0.523
  Location                                                                                                                        
   Asia                      11                 0.476 (0.457, 0.495)    \<0.001                          0.480 (0.422, 0.539)     0.751
   Non-Asia                  2                  0.533 (0.480, 0.586)    0.047                            0.545 (0.435, 0.651)     ---
  Tumor stage                                                                                                                     
   III and IV                6                  0.552 (0.522, 0.582)    0.028                            0.542 (0.492, 0.592)     0.209
  Treatment                                                                                                                       
   Chemotherapy              3                  0.569 (0.530, 0.607)    0.042                            0.552 (0.478, 0.624)     0.096
   Chemo- and radiotherapy   2                  0.555 (0.483, 0.625)    0.061                            0.540 (0.400, 0.674)     ---
   Mixed                     7                  0.444 (0.422, 0.466)    \<0.001                          0.448 (0.387, 0.510)     0.739
  PLR criteria                                                                                                                    
   High (\>150)              4                  0.404 (0.373, 0.435)    \<0.001                          0.435 (0.321, 0.556)     0.148
   Low (≤150)                9                  0.518 (0.497, 0.540)    0.006                            0.519 (0.482, 0.557)     0.976

NLR: neutrophil-to-lymphocyte ratio; PLR: platelet-to-lymphocyte ratio; CI: confidence interval. "Mixed" treatment indicates surgery plus chemotherapy/radiotherapy.

###### 

Correlation between lymphocyte-associated parameters and survival rate.

                             Number of subset   Fixed effect (95% CI)   Heterogeneity test (*P* value)   Random effect (95% CI)   Egger\'s test (*P* value)
  -------------------------- ------------------ ----------------------- -------------------------------- ------------------------ ---------------------------
  *NLR*                                                                                                                           
  Overall                    35                 1.147 (0.116, 1.180)    \<0.001                          1.737 (1.502, 2.009)     \<0.001
  Location                                                                                                                        
   Asia                      26                 1.129 (1.097, 1.162)    \<0.001                          1.763 (1.470, 2.114)     \<0.001
   Non-Asia                  9                  1.544 (1.365, 1.747)    0.054                            1.626 (1.360, 1.946)     0.010
  Tumor stage                                                                                                                     
   I and II                  1                  1.859 (1.272, 2.717)    1.000                            1.859 (1.272, 2.717)     ---
   III and IV                17                 1.733 (1.563, 1.921)    \<0.001                          1.929 (1.509, 2.467)     0.144
  Treatment                                                                                                                       
   Surgery                   1                  1.510 (1.148, 1.986)    1.000                            1.510 (1.148, 1.986)     ---
   Chemotherapy              13                 1.797 (1.603, 2.015)    \<0.001                          2.043 (1.584, 2636)      0.061
   Chemo- and radiotherapy   2                  1.333 (0.917, 1.937)    0.020                            0.922 (0.269, 3.162)     ---
   Mixed                     18                 1.110 (1.078, 1.143)    \<0.001                          1.670 (1.385, 2.013)     \<0.001
  NLR criteria                                                                                                                    
   High (\>4)                18                 1.954 (1.749, 2.183)    \<0.001                          2.001 (1.602, 2.499)     0.671
   Low (≤4)                  17                 1.107 (1.075, 1.139)    \<0.001                          1.508 (1.285, 1.770)     \<0.001
  *PLR*                                                                                                                           
  Overall                    14                 1.009 (1.007, 1.011)    0.009                            1.143 (1.037, 1.259)     0.008
  Location                                                                                                                        
   Asia                      11                 1.009 (1.007, 1.011)    0.026                            1.121 (1.010, 1.243)     0.038
   Non-Asia                  3                  1.217 (1.013, 1.462)    0.171                            1.239 (0.968, 1.587)     0.232
  Tumor stage                                                                                                                     
   III and IV                6                  1.155 (1.002, 1.332)    0.281                            1.158 (0.983, 1.364)     0.828
  Treatment                                                                                                                       
   Chemotherapy              3                  1.053 (0.861, 1.287)    0.488                            1.053 (0.861, 1.287)     0.203
   Chemo- and radiotherapy   2                  1.282 (0.937, 1.753)    0.075                            1.206 (0.674, 2.158)     ---
   Mixed                     8                  1.009 (1.007, 1.011)    0.021                            1.125 (1.009, 1.254)     0.043
  PLR criteria                                                                                                                    
   High (\>150)              5                  1.009 (1.007, 1.011)    0.001                            1.219 (0.992, 1.499)     0.080
   Low (≤150)                9                  1.105 (1.000, 1.222)    0.561                            1.105 (1.000, 1.222)     0.471

NLR: neutrophil-to-lymphocyte ratio; PLR: platelet-to-lymphocyte ratio; CI: confidence interval. "Mixed" treatment indicates surgery plus chemotherapy/radiotherapy.
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